This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

EZETROL® (ezetimibe) indication and IMPROVE-IT trial

Prescribing Information

Length: 02:03

This short video highlights EZETROL indications: licenced to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.1

It includes a summary of IMPROVE-IT, a cardiovascular outcomes trial which led to a licence update for EZETROL.

IMPROVE-IT was a double-blind, randomised trial in 18,144 patients. These patients had been hospitalised for an ACS within the preceding 10 days with LDL-C levels of 1.3 - 2.6 mmol/L if receiving lipid-lowering therapy or 1.3 - 3.2 mmol/L if not receiving lipid-lowering therapy. Combination of simvastatin 40 mg + ezetimibe 10 mg was compared with simvastatin 40mg + placebo. Primary endpoint: Composite of CV death, nonfatal MI, unstable angina requiring hospitalisation, coronary revascularisation (≥30 days after randomisation) or nonfatal stroke).2 The median follow-up was 6 years.

References

  1. EZETROL Summary of Product Characteristics.
  2. Cannon 2015 Cannon C. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes NEJM 2015; 1 Publication of the IMPROVE-IT study.

More information about EZETROL® (ezetimibe):

Supporting documentation

CARD-1252030-0001 | Date of Preparation: September 2018